Replies to post #47 on Tianyin Pharmaceutical Co., Inc. (TPI)

[surf1944]

7:33AM Tianyin Pharma Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from China's SFDA (TPI) 1.72 : Co announces it has received the production license for its anti-diabetic drug Gliclazide Tablets from China's State Food and Drug Administration. The national pharmaceutical certificate number for TPI's new Gliclazide Tablets is also issued: H20113233.

[surf1944]

3:27PM Tianyin Pharma signs Macrolide API International sales and marketing agreement ; forecasts $30 mln domestic Azithromycin API revenue in China for first year of operation (TPI) 1.50 +0.02 : Co signed sales and marketing agreement with RELATIONS International. The co forecasts $30 million domestic Azithromycin API revenue in China for the first year of operation from its Jiangchuan macrolide facility that has an annual manufacturing capacity of 250 tons. The international sales revenue from macrolide API is expected to contribute additional revenue for TPI.